Тромбоз, гемостаз и реология

Tromboz, Gemostaz I Reologiya
scientific and practical journal

ISSN 2078–1008 (Print); ISSN 2687-1483 (online)
2023, Original papers
2023

Dynamics of MCP‐1 and IP‐10 levels in obese patients under anticoagulant therapy in COVID‐19: 616.14-005.6/.7-02:616.151.5

Original papers
Published 2024-04-03
Roman E. Kalinin
Pavlov Ryazan State Medical University, Ministry of Health of the Russian Federation; 9 Vysokovoltnaya Str., Ryazan 390026, Russia;
ФГБОУ ВО «Рязанский государственный медицинский университет имени академика И.П.Павлова» Министерства здравоохранения Российской Федерации; Россия, 390026 Рязань, ул. Высоковольтная, 9;
Igor A. Suchkov
Pavlov Ryazan State Medical University, Ministry of Health of the Russian Federation; 9 Vysokovoltnaya Str., Ryazan 390026, Russia;
ФГБОУ ВО «Рязанский государственный медицинский университет имени академика И.П.Павлова» Министерства здравоохранения Российской Федерации; Россия, 390026 Рязань, ул. Высоковольтная, 9;
Andrey B. Agapov
Pavlov Ryazan State Medical University, Ministry of Health of the Russian Federation; 9 Vysokovoltnaya Str., Ryazan 390026, Russia; Ryazan Regional Clinical Hospital; 3а Internatsionalnaya Str., Ryazan 390039, Russia;
ФГБОУ ВО «Рязанский государственный медицинский университет имени академика И.П.Павлова» Министерства здравоохранения Российской Федерации; Россия, 390026 Рязань, ул. Высоковольтная, 9; ГБУ Рязанской области «Областная клиническая больница»; Россия, 390039 Рязань, ул. Интернациональная, 3а;
Nina D. Mzhavanadze
Pavlov Ryazan State Medical University, Ministry of Health of the Russian Federation; 9 Vysokovoltnaya Str., Ryazan 390026, Russia; Ryazan City Clinical Emergency Hospital; 11 Dzerzhinsky Str., Ryazan 3900139, Russia
ФГБОУ ВО «Рязанский государственный медицинский университет имени академика И.П.Павлова» Министерства здравоохранения Российской Федерации; Россия, 390026 Рязань, ул. Высоковольтная, 9; ГБУ Рязанской области «Городская клиническая больница скорой медицинской помощи»; Россия, 390013 Рязань, ул. Дзержинского, 11
Vladislav O. Povarov
Pavlov Ryazan State Medical University, Ministry of Health of the Russian Federation; 9 Vysokovoltnaya Str., Ryazan 390026, Russia;
ФГБОУ ВО «Рязанский государственный медицинский университет имени академика И.П.Павлова» Министерства здравоохранения Российской Федерации; Россия, 390026 Рязань, ул. Высоковольтная, 9;
Alexander A. Nikiforov
Pavlov Ryazan State Medical University, Ministry of Health of the Russian Federation; 9 Vysokovoltnaya Str., Ryazan 390026, Russia;
ФГБОУ ВО «Рязанский государственный медицинский университет имени академика И.П.Павлова» Министерства здравоохранения Российской Федерации; Россия, 390026 Рязань, ул. Высоковольтная, 9;

Keywords

novel coronavirus infection COVID‐19
venous thromboembolic complications
VTEC
bleedings
monocyte chemoattractant protein‐1
MCP‐1
interferon‐gamma‐inducible protein‐10
IP‐10
  Full Text

Abstract

Summary. Introduction. The pathogenesis of COVID-19 is based on the interplay between coagulopathy and inflammation, highlighting the importance of laboratory assessment of coagulation and proinflammatory parameters in obese patients with COVID-19. Aim: to evaluate the changes in monocyte chemoattractant protein-1 (MCP-1) and interferon-gamma-inducible protein-10 (IP-10) levels in obese patients receiving different anticoagulant prophylaxis options for COVID-19. Materials and Methods. A prospec- tive observational study was conducted between July 2021 and January 2022, examining 370 patients: 135 men and 235 women with an average age of 61.1 years (23–93). Depending on the presence of obesity and anticoagulant option, patients were divided into 4 groups: group 1 — 113 non-obese individuals + low molecular weight heparin (LMWH) prophylaxis, group 2 — 58 non-obese individuals + unfractionated heparin (UFH) prophylaxis, group 3 — 76 obese individuals + LMWH prophylaxis, group 4 — 66 obese individuals+UFH prophylaxis. The frequency of venous thromboembolic complications (VTEC), and bleeding, as well as the changes in laboratory parameters were evaluated during treatment. These parameters included leukocyte, platelet, and erythro- cyte counts, hemoglobin level, erythrocyte sedimentation rate (ESR), procalcitonin, C-reactive protein (CRP), ferritin, fibrinogen, D-dimer, activated partial thromboplastin time (APTT), prothrombin time (PT), and specific markers for thrombosis and inflam- mation, such as MCP-1 and IP-10. Results. At the beginning of treatment (upon admission to the hospital), all patients exhibited high levels of all proinflammatory markers and coagulation parameters. At the end of treatment (at discharge from the hospital), both obese and non-obese patients demonstrated a decrease in CRP and IP-10 concentrations, while the MCP-1 level decreased only in patients treated with LMWH. The incidence of VTEC and bleeding was lower in both obese and non-obese patients who received LMWH compared with those treated with UFH (p<0.001). Conclusion. The decrease in IP-10 and MCP-1 levels is more pronounced in both obese and non-obese patients who receive LMWH, with a low incidence of VTEC and bleeding, as opposed to patients treated with UFH.

For citation: Kalinin R.E., Suchkov I.A., Agapov А.В., Mzhavanadze N.D., Povarov V.O., Nikiforov A.A. Dynamics of MCP-1 and IP-10 level in obese patients under anticoagulant therapy in COVID-19. Tromboz, gemostaz i reologiya. 2023;(4):19–30. (In Russ.).

References

  1. Kalinin R.E., Suchkov I.A., Povarov V.O. et al. Hemostasis system in patients with bradycardias after the implantation of electronicdualchamberpace makers. Rossijskij mediko-biologicheskij vestnik imeni akademika I. P. Pavlova. 2021;29(4):497–504. (In Russ.). DOI: 10.17816/PAVLOVJ79285.
  2. Kalinin R.E., Suchkov I.A., Agapov A.B. et al. Coagulopathy and risk factors in patients with severe COVID-19. Tromboz, gemostaz i reologiya. 2022;(4):64–74. (In Russ.). DOI: 10.25555/THR.2022.4.1042.
  3. Han H., Xie L., Liu R. et al. Analysis of heart injury laboratory parameters in 273 COVID-19 patients in one hospital in Wuhan, China. J Med Virol. 2020;92(7):819–23. DOI: 10.1002/jmv.25809.
  4. Vertkin A. L., Avdeev S. N., Roitman E. V. et al. Treatment of COVID-19 from the perspective of endotheliopathy correction and prevention of thrombotic complications. The agreed position of the experts. Profilakticheskaya medicina. 2021;24(4):45– 51. (In Russ.). DOI: 10.17116/profmed20212404145.
  5. Yousuf S.D., Ganie M.A., Urwat U. et al. Oral contraceptive pill (OCP) treatment alters the gene expression of intercellular adhesion molecule-1 (ICAM-1), tumor necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-1) and plasminogen activator inhibitor-1 (PAI-1) in polycystic ovary syndrome (PCOS) women compared to drug-naive PCOS women. BMC Womens Health. 2023;23(1):68. DOI: 10.1186/s12905-023-02187-5.
  6. Kalinin R.E., Suchkov I.A., Agapov A.B. et al. Analysis of risk factors of venous thromboembolic complications and of different variants of anticoagulant therapy in patients with new coronavirus infection. Rossijskij mediko-biologicheskij vestnik imeni akademika I.P. Pavlova. 2023;31(2):243–54. (In Russ.). DOI: 10.17816/ PAVLOVJ110956.
  7. Yoshimura T. The production of monocyte chemoattractant protein-1 (MCP-1)/CCL2 in tumor microenvironments. Cytokine. 2017;98:71–8. DOI: 10.1016/j.cyto.2017.02.001.
  8. Lupieri A., Smirnova N.F., Solinhac R. et al. Smooth muscle cellsderived CXCL10 prevents endothelial healing through PI3Kγdependent T cells response. Cardiovasc Res. 2020;116(2):438–49. DOI: 10.1093/CVR/CVZ122.
  9. Interim guidelines. Prevention, diagnosis and treatment of novel coronavirus infection (COVID-19). Version 11 (07.05.2021). Moscow: Ministerstvo zdravoohraneniya Rossijskoj Federacii, 2021. 225 рp. (In Russ.). Available at: https://rmapo.ru/uploads/korona/МР_ COVID-19-v11.pdf. [Accessed: 20.06.2023].
  10. Interim guidelines. Prevention, diagnosis and treatment of novel coronavirus infection (COVID-19). Version 12 (21.09.2021). Moscow: Ministerstvo zdravoohraneniya Rossijskoj Federacii, 2021. 232 рp. (In Russ.). Available at: https://static-0.minzdrav.gov.ru/system/ attachments/attaches/000/058/075/original/ВМР_COVID-19_ V12.pdf. [Accessed: 20.06.2023].
  11. Interim guidelines. Prevention, diagnosis and treatment of novel coronavirus infection (COVID-19). Version 13 (14.10.2021). Moscow: Ministerstvo zdravoohraneniya Rossijskoj Federacii, 2021. 237 рp. (In Russ.). Available at: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/058/211/original/BMP-13.pdf. [Accessed: 20.06.2023].
  12. Interim guidelines. Prevention, diagnosis and treatment of novel coronavirus infection (COVID-19). Version 14 (27.12.2021). Moscow: Ministerstvo zdravoohraneniya Rossijskoj Federacii, 2021. 233 рp. (In Russ.). Available at: https://static-0.minzdrav.gov.ru/system/ attachments/attaches/000/059/041/original/ВМР_COVID-19_ V14_27–12–2021.pdf. [Accessed: 20.06.2023].
  13. Schulman S., Kearon С.; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692–4. DOI: 10.1111/j.1538-7836.2005.01204.x.
  14. Romantsova T.R., Sych Yu.P. Immunometabolism and metainflammation in obesity. Ozhirenie i metabolizm. 2019;16(4):3–17 (In Russ.). DOI: 10.14341/omet12218.
  15. Borodina I.A., Selezneva I.A., Borisova O.V. et al. Blood groups and secretory state in COVID-19. Nauka molodyh (Eruditio Juvenium). 2021;9(4):589–96. (In Russ.). DOI: 10.23888/HMJ202194589-596.
  16. Mangion K., Morrow A., Bagot C. et al. The chief scientist office cardiovascular and pulmonary imaging in SARS coronavirus disease-19 (CISCO-19) study. Cardiovasc Res. 2020;116(14):2185– 96. DOI: 10.1093/cvr/cvaa209.
  17. Han M.S., Jung D.Y., Morel C. et al. JNK expression by macrophages promotes obesity-induced insulin resistance and inflammation. Science. 2013;339(6116):218–22. DOI: 10.1126/science.1227568.
  18. Kanda H., Tateya S., Tamori Y. et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J Clin Invest. 2006;116(6):1494–505. DOI: 10.1172/JCI26498.
  19. Levi M., van der Poll T., Schultz M. Infection and inflammation as risk factors for thrombosis and atherosclerosis. Semin Thromb Hemost. 2012;38(5):506–14. DOI: 10.1055/s-0032-1305782.
  20. Kalinin R.E., Suchkov I.A., Agapov A.B. The effectiveness of the various options of anticoagulant therapy for the treatment of the patients with thrombosis of the deep veins of the lower extremities in the routine clinical practice. Flebologiya. 2017;11(1):21–7. (In Russ.). DOI: 10.17116/flebo201711121-27.
  21. van den Borne P., Quax P.H., Hoefer I.E., Pasterkamp G. The multifaceted functions of CXCL10 in cardiovascular disease. Biomed Res Int. 2014;2014:893106. DOI: 10.1155/2014/893106.
  22. Mir Seyed Nazari P., Marosi C., Moik F. et al. Low systemic levels of chemokine C–C motif ligand 3 (CCL3) are associated with a high risk of venous thromboembolism in patients with glioma. Cancers (Basel). 2019;11(12):2020. DOI: 10.3390/cancers11122020.
  23. Chen Y., Wang J., Liu C. et al. IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19. Mol Med. 2020;26(1):97. DOI: 10.1186/s10020-020-00230-x.
  24. Walenga J.M., Jackson C.M., Kessler C.M. Low molecular weight heparins differ substantially: impact on developing biosimilar drugs. Semin Thromb Hemost. 2011;37(3):322–7. DOI: 10.1055/ s-0031-1274515.
  25. Mulloy B., Hogwood J., Gray E. et al. Pharmacology of heparin and related drugs. Pharmacol Rev. 2016;68(1):76–141. DOI: 10.1124/ pr.115.011247.
  26. Heinzelmann M., Miller M., Platz A. et al. Heparin and enoxaparin enhance endotoxin-induced tumor necrosis factor-alpha production in human monocytes. Ann Surg. 1999;229(4):542–50. DOI: 10.1097/00000658-199904000-00014.
  27. Mousa S. A., Fareed J., Iqbal O., Kaiser B. Tissue factor pathway inhibitor in thrombosis and beyond. Methods Mol Med. 2004;93:133–55. DOI: 10.1385/1-59259-658-4:133.
  28. Tovar A.M., Teixeira L.A., Rembold S.M. et al. Bovine and porcine heparins: different drugs with similar effects on human haemodialysis. BMC Res Notes. 2013;6:230. DOI: 10.1186/1756-0500-6-230.